JUVENTAS THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION AND PHASE 2B PROTOCOL ALLOWANCE FOR NOVEL HEART FAILURE GENE THERAPY

Press/Media: Press / Media

PeriodJun 27 2015

Media coverage

1

Media coverage